Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jaip.2021.10.049
Title: Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality
Authors: Ren, J
Pang, W
Luo, Y
Cheng, D
Qiu, K
Rao, Y
Zheng, Y
Dong, Y
Peng, J
Hu, Y
Ying, Z
Yu, H
Zeng, X
Zong, Z
Liu, G
Wang, D 
Wang, G
Zhang, W
Xu, W
Zhao, Y
Keywords: Allergic rhinitis
Asthma
COVID-19
Glucocorticoids
Long-term medications
Adult
Asthma
COVID-19
COVID-19 Testing
Female
Hospitalization
Humans
Male
Rhinitis, Allergic
SARS-CoV-2
Issue Date: 1-Jan-2022
Publisher: Elsevier BV
Citation: Ren, J, Pang, W, Luo, Y, Cheng, D, Qiu, K, Rao, Y, Zheng, Y, Dong, Y, Peng, J, Hu, Y, Ying, Z, Yu, H, Zeng, X, Zong, Z, Liu, G, Wang, D, Wang, G, Zhang, W, Xu, W, Zhao, Y (2022-01-01). Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality. Journal of Allergy and Clinical Immunology: In Practice 10 (1) : 124-133. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jaip.2021.10.049
Abstract: Background: It remains unclear if patients with allergic rhinitis (AR) and/or asthma are susceptible to corona virus disease 2019 (COVID-19) infection, severity, and mortality. Objective: To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19. Methods: Demographic and clinical data of 70,557 adult participants completed SARS-CoV-2 testing between March 16 and December 31, 2020, in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization, and mortality in relation to pre-existing AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality. Results: Patients with AR of all ages had lower positive rates of SARS-CoV-2 tests (relative risk [RR]: 0.75, 95% confidence interval [CI]: 0.69-0.81, P < .001), with lower susceptibility in males (RR: 0.74, 95% CI: 0.65-0.85, P < .001) than females (RR: 0.8, 95% CI: 0.72-0.9, P < .001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR: 0.93, 95% CI: 0.86-1, P = .044) instead of elderlies. In contrast, patients with asthma tested positively had higher risk of hospitalization (RR: 1.42, 95% CI: 1.32-1.54, P < .001). Neither AR nor asthma had an impact on COVID-19 mortality. None of conventional medications for AR or asthma, for example, antihistamines, corticosteroids, or β2 adrenoceptor agonists, showed association with COVID-19 infection or severity. Conclusion: AR (all ages) and asthma (aged <65) act as protective factors against COVID-19 infection, whereas asthma increases risk for COVID-19 hospitalization. None of the long-term medications had a significant association with infection, severity, and mortality of COVID-19 among patients with AR and/or asthma.
Source Title: Journal of Allergy and Clinical Immunology: In Practice
URI: https://scholarbank.nus.edu.sg/handle/10635/227544
ISSN: 22132198
22132201
DOI: 10.1016/j.jaip.2021.10.049
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality.pdf724.02 kBAdobe PDF

OPEN

Post-print Available on 01-01-2023

SCOPUSTM   
Citations

8
checked on Oct 1, 2022

Page view(s)

32
checked on Sep 29, 2022

Download(s)

2
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.